| Survival: | 7.0 months |
| Toxicity Grade: | 3 |
| Treatments: | Chemotherapy |
| Drugs: | |
| Country: | Netherlands |
| City/State/Province: | Amsterdam |
| Hospital: | The Netherlands Cancer Institute |
| Journal: | Link |
| Date: | 2/2003 |
| Description: |
| Patients: This Phase II study involved 24 patients with malignant pleural mesothelioma; 19 men and 5 women. The median age was 63 years. Treatment: The treatment consisted of the drug raltitrexed (tomudex). This agent inhibits the enzyme thymidylate synthase which is involved in the synthesis of DNA. Toxicity: Grade 3-4 toxicities included anorexia, shortness of breath/dyspnea, hematologic, febrile neutropenia, nausea/vomiting, neurological toxicity, chest pain, pleuritic pain, and cough. Results: The overall median survival was 7 months. Support: AstraZeneca provided the drug (Tomudex) free of charge. Correspondence: P. Baas, MD |